Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets

Fig. 2

Neoadjuvant therapies induce local tumor dormancy in patients with early stage breast cancer. Patients with HER2-positive breast cancer (stages I–III) received neoadjuvant Pertuzumab, Trastuzumab, Docetaxel, and Carboplatin, and those with TNBC received neoadjuvant Taxol, Carboplatin, Adriamycin, and Cytoxan, followed by surgery. a Tumor biopsies (before) and surgical excisions (after), neoadjuvant therapies of patients with triple-negative breast cancer or HER2-positive breast cancer who partially responded (PR) to neoadjuvant therapies, were subjected to Ki67 staining. IHC analysis showing Ki67+ (brown) and Ki67− (blue), and percent Ki67− or Ki67+ in tumor biopsies (before, n = 4) or surgical excisions (after, n = 4) were analyzed using the Vectra® Polaris™ Automated Quantitative Pathology Imaging System and InForm software (PerkinElmer) (1 × 1 field, 20× resolution). b Biopsy specimens of patients with early stage breast cancer who showed a complete response (CR) or no response (NR) to neoadjuvant therapies (5 patients per group) were analyzed for the expression of Ki67

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us